Blau syndrome-associated Nod2 mutation alters expression of full-length NOD2 and limits responses to muramyl dipeptide in knock-in mice

Jae Dugan, Eric Griffiths, Paige Snow, Holly Rosenzweig, Ellen Lee, Brieanna Brown, Daniel Carr, Carlos Rose, James (Jim) Rosenbaum, Michael Davey

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

The biochemical mechanism by which mutations in nucleotide-binding oligomerization domain containing 2 (NOD2) cause Blau syndrome is unknown. Several studies have examined the effect of mutations associated with Blau syndrome in vitro, but none has looked at the implication of the mutations in vivo. To test the hypothesis that mutated NOD2 causes alterations in signaling pathways downstream of NOD2, we created a Nod2 knock-in mouse carrying the most common mutation seen in Blau syndrome, R314Q (corresponding to R334Q in humans). The endogenous regulatory elements of mouse Nod2 were unaltered. R314Q mice showed reduced cytokine production in response to i.p. and intravitreal muramyl dipeptide (MDP). Macrophages from R314Q mice showed reduced NF-kB and IL-6 responses, blunted phosphorylation of MAPKs, and deficient ubiquitination of receptorinteracting protein 2 in response to MDP. R314Q mice expressed a truncated 80-kDa form of NOD2 that was most likely generated by a posttranslational event because there was no evidence for a stop codon or alternative splicing event. Human macrophages from two patients with Blau syndrome also showed a reduction of both cytokine production and phosphorylation of p38 in response to MDP, indicating that both R314Q mice and cells from patients with Blau syndrome show reduced responses to MDP. These data indicate that the R314Q mutation when studied with the Nod2 endogenous regulatory elements left intact is associated with marked structural and biochemical changes that are significantly different from those observed from studies of the mutation using overexpression, transient transfection systems.

Original languageEnglish (US)
Pages (from-to)349-357
Number of pages9
JournalJournal of Immunology
Volume194
Issue number1
DOIs
StatePublished - Jan 1 2015

Fingerprint

Acetylmuramyl-Alanyl-Isoglutamine
Nucleotides
Mutation
Macrophages
Phosphorylation
Cytokines
Terminator Codon
NF-kappa B
Ubiquitination
Alternative Splicing
Transfection
Blau syndrome
Interleukin-6

ASJC Scopus subject areas

  • Immunology

Cite this

Blau syndrome-associated Nod2 mutation alters expression of full-length NOD2 and limits responses to muramyl dipeptide in knock-in mice. / Dugan, Jae; Griffiths, Eric; Snow, Paige; Rosenzweig, Holly; Lee, Ellen; Brown, Brieanna; Carr, Daniel; Rose, Carlos; Rosenbaum, James (Jim); Davey, Michael.

In: Journal of Immunology, Vol. 194, No. 1, 01.01.2015, p. 349-357.

Research output: Contribution to journalArticle

@article{4945fb81170b421aae05ec64ea3c8234,
title = "Blau syndrome-associated Nod2 mutation alters expression of full-length NOD2 and limits responses to muramyl dipeptide in knock-in mice",
abstract = "The biochemical mechanism by which mutations in nucleotide-binding oligomerization domain containing 2 (NOD2) cause Blau syndrome is unknown. Several studies have examined the effect of mutations associated with Blau syndrome in vitro, but none has looked at the implication of the mutations in vivo. To test the hypothesis that mutated NOD2 causes alterations in signaling pathways downstream of NOD2, we created a Nod2 knock-in mouse carrying the most common mutation seen in Blau syndrome, R314Q (corresponding to R334Q in humans). The endogenous regulatory elements of mouse Nod2 were unaltered. R314Q mice showed reduced cytokine production in response to i.p. and intravitreal muramyl dipeptide (MDP). Macrophages from R314Q mice showed reduced NF-kB and IL-6 responses, blunted phosphorylation of MAPKs, and deficient ubiquitination of receptorinteracting protein 2 in response to MDP. R314Q mice expressed a truncated 80-kDa form of NOD2 that was most likely generated by a posttranslational event because there was no evidence for a stop codon or alternative splicing event. Human macrophages from two patients with Blau syndrome also showed a reduction of both cytokine production and phosphorylation of p38 in response to MDP, indicating that both R314Q mice and cells from patients with Blau syndrome show reduced responses to MDP. These data indicate that the R314Q mutation when studied with the Nod2 endogenous regulatory elements left intact is associated with marked structural and biochemical changes that are significantly different from those observed from studies of the mutation using overexpression, transient transfection systems.",
author = "Jae Dugan and Eric Griffiths and Paige Snow and Holly Rosenzweig and Ellen Lee and Brieanna Brown and Daniel Carr and Carlos Rose and Rosenbaum, {James (Jim)} and Michael Davey",
year = "2015",
month = "1",
day = "1",
doi = "10.4049/jimmunol.1402330",
language = "English (US)",
volume = "194",
pages = "349--357",
journal = "Journal of Immunology",
issn = "0022-1767",
publisher = "American Association of Immunologists",
number = "1",

}

TY - JOUR

T1 - Blau syndrome-associated Nod2 mutation alters expression of full-length NOD2 and limits responses to muramyl dipeptide in knock-in mice

AU - Dugan, Jae

AU - Griffiths, Eric

AU - Snow, Paige

AU - Rosenzweig, Holly

AU - Lee, Ellen

AU - Brown, Brieanna

AU - Carr, Daniel

AU - Rose, Carlos

AU - Rosenbaum, James (Jim)

AU - Davey, Michael

PY - 2015/1/1

Y1 - 2015/1/1

N2 - The biochemical mechanism by which mutations in nucleotide-binding oligomerization domain containing 2 (NOD2) cause Blau syndrome is unknown. Several studies have examined the effect of mutations associated with Blau syndrome in vitro, but none has looked at the implication of the mutations in vivo. To test the hypothesis that mutated NOD2 causes alterations in signaling pathways downstream of NOD2, we created a Nod2 knock-in mouse carrying the most common mutation seen in Blau syndrome, R314Q (corresponding to R334Q in humans). The endogenous regulatory elements of mouse Nod2 were unaltered. R314Q mice showed reduced cytokine production in response to i.p. and intravitreal muramyl dipeptide (MDP). Macrophages from R314Q mice showed reduced NF-kB and IL-6 responses, blunted phosphorylation of MAPKs, and deficient ubiquitination of receptorinteracting protein 2 in response to MDP. R314Q mice expressed a truncated 80-kDa form of NOD2 that was most likely generated by a posttranslational event because there was no evidence for a stop codon or alternative splicing event. Human macrophages from two patients with Blau syndrome also showed a reduction of both cytokine production and phosphorylation of p38 in response to MDP, indicating that both R314Q mice and cells from patients with Blau syndrome show reduced responses to MDP. These data indicate that the R314Q mutation when studied with the Nod2 endogenous regulatory elements left intact is associated with marked structural and biochemical changes that are significantly different from those observed from studies of the mutation using overexpression, transient transfection systems.

AB - The biochemical mechanism by which mutations in nucleotide-binding oligomerization domain containing 2 (NOD2) cause Blau syndrome is unknown. Several studies have examined the effect of mutations associated with Blau syndrome in vitro, but none has looked at the implication of the mutations in vivo. To test the hypothesis that mutated NOD2 causes alterations in signaling pathways downstream of NOD2, we created a Nod2 knock-in mouse carrying the most common mutation seen in Blau syndrome, R314Q (corresponding to R334Q in humans). The endogenous regulatory elements of mouse Nod2 were unaltered. R314Q mice showed reduced cytokine production in response to i.p. and intravitreal muramyl dipeptide (MDP). Macrophages from R314Q mice showed reduced NF-kB and IL-6 responses, blunted phosphorylation of MAPKs, and deficient ubiquitination of receptorinteracting protein 2 in response to MDP. R314Q mice expressed a truncated 80-kDa form of NOD2 that was most likely generated by a posttranslational event because there was no evidence for a stop codon or alternative splicing event. Human macrophages from two patients with Blau syndrome also showed a reduction of both cytokine production and phosphorylation of p38 in response to MDP, indicating that both R314Q mice and cells from patients with Blau syndrome show reduced responses to MDP. These data indicate that the R314Q mutation when studied with the Nod2 endogenous regulatory elements left intact is associated with marked structural and biochemical changes that are significantly different from those observed from studies of the mutation using overexpression, transient transfection systems.

UR - http://www.scopus.com/inward/record.url?scp=84919628687&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84919628687&partnerID=8YFLogxK

U2 - 10.4049/jimmunol.1402330

DO - 10.4049/jimmunol.1402330

M3 - Article

VL - 194

SP - 349

EP - 357

JO - Journal of Immunology

JF - Journal of Immunology

SN - 0022-1767

IS - 1

ER -